LG1 wrote:This looks exciting, promising. Hopeful!!!
NewRon wrote:Yes, it does, thanks for highlighting it!
Anyone else with more experience than me of reading these studies care to weigh in on it?
I added some more below from the conclusion LG1 cited. Interesting that the researchers see this as a better version of the anti-amyloid drug donanemab, which has started Trailblazer-ALZ-3
a Phase III trial of 3300 cognitively unimpaired people with amyloid beta and "early tau" on PET scans. The researchers here seem to predict that their antibody will not cause the ARIA-E (Amyloid-related imaging abnormalities-brain edema) that occurs in about 25% of the donanemab trial participants.
Sounds like they are seeking vaccine companies to aid in development and funding from either the EU or US for early Phase 1 safety trials. It's a promise that may be 10 years off, given the time needed for careful human studies. I hope they'll be invited to present more at the 2022 Alzheimer's Association conference.
The novel TAPAS family of antibodies have revealed two new attractive options for therapeutic intervention in AD... The lead therapeutic antibody for clinical assessment is TAP01_04, which is a humanised variant of TAP01 retaining the high specificity and affinity of the mouse parent antibody ...For a trail blazing vaccine-based approach to AD, formulation of the candidate cyclised Aβ peptides is likely to be a key factor to ensure a strong immune response and will require expertise from specialist vaccine development organisations. The design of the TRAILBLAZER-ALZ phase II registration quality trial to evaluate safety, tolerability and efficacy of donanemab will be helpful to design clinical trials targeting the TAPAS epitope. As donanemab completely cleared plaques in two-thirds of participants and slowed cognitive decline in some patients, the pathological status appears crucial for a successful treatment strategy.